Cargando…

Heterogeneous Mechanisms of Secondary Resistance and Clonal Selection in Sarcoma during Treatment with Nutlin

Nutlin inhibits TP53-MDM2 interaction and is under investigation in soft-tissue sarcomas (STS) and other malignancies. Molecular mechanisms of secondary resistance to nutlin in STS are unknown. We performed whole-transcriptome sequencing (RNA-seq) on three pretreatment and secondary resistant STS ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Laroche, Audrey, Tran-Cong, Kevin, Chaire, Vanessa, Lagarde, Pauline, Hostein, Isabelle, Coindre, Jean-Michel, Chibon, Frederic, Neuville, Agnes, Lesluyes, Tom, Lucchesi, Carlo, Italiano, Antoine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2015
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4591276/ https://www.ncbi.nlm.nih.gov/pubmed/26427052 http://dx.doi.org/10.1371/journal.pone.0137794

Ejemplares similares

PRIMA-1(MET) induces death in soft-tissue sarcomas cell independent of p53
por: Grellety, Thomas, et al.
Publicado: (2015)

Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Analysis of the Peritumoral Tissue Unveils Cellular Changes Associated with a High Risk of Recurrence
por: Michot, Audrey, et al.
Publicado: (2023)

BRCA1 haplotype and clinical benefit of trabectedin in soft-tissue sarcoma patients
por: Laroche-Clary, A, et al.
Publicado: (2015)

Gene expression identifies heterogeneity of metastatic behavior among high-grade non-translocation associated soft tissue sarcomas
por: Skubitz, Keith M, et al.
Publicado: (2014)

Dual inhibition of the PI3K/AKT/mTOR pathway suppresses the growth of leiomyosarcomas but leads to ERK activation through mTORC2: biological and clinical implications
por: Fourneaux, Benjamin, et al.
Publicado: (2016)

ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status
por: Laroche-Clary, Audrey, et al.
Publicado: (2020)

Recurrent DMD Deletions Highlight Specific Role of Dp71 Isoform in Soft-Tissue Sarcomas
por: Mauduit, Olivier, et al.
Publicado: (2019)

The CINSARC signature as a prognostic marker for clinical outcome in multiple neoplasms
por: Lesluyes, Tom, et al.
Publicado: (2017)

RCBTB1 Deletion Is Associated with Metastatic Outcome and Contributes to Docetaxel Resistance in Nontranslocation-Related Pleomorphic Sarcomas
por: Mauduit, Olivier, et al.
Publicado: (2019)

Prognostic Value of PLAGL1-Specific CpG Site Methylation in Soft-Tissue Sarcomas
por: Peille, Anne-Lise, et al.
Publicado: (2013)

MED12 Alterations in Both Human Benign and Malignant Uterine Soft Tissue Tumors
por: Pérot, Gaëlle, et al.
Publicado: (2012)

MDM2 antagonists synergize with PI3K/mTOR inhibition in well-differentiated/dedifferentiated liposarcomas
por: Laroche, Audrey, et al.
Publicado: (2017)

Expression and prognostic significance of PDGF ligands and receptors across soft tissue sarcomas
por: Brahmi, M., et al.
Publicado: (2021)

Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma
por: Dufresne, A., et al.
Publicado: (2020)

Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas
por: Laroche-Clary, Audrey, et al.
Publicado: (2017)

Heterogeneity in sarcoma cell lines reveals enhanced motility of tetraploid versus diploid cells
por: Jemaà, Mohamed, et al.
Publicado: (2016)

Antitumor Effects of PRMT5 Inhibition in Sarcomas
por: Verbeke, Stéphanie, et al.
Publicado: (2023)

Prognostic impact of circulating tumor cells in patients with soft‐tissue sarcomas: a prospective study
por: Blanchi, Julie, et al.
Publicado: (2023)

High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies
por: Toulmonde, Maud, et al.
Publicado: (2020)

ATRX Alteration Contributes to Tumor Growth and Immune Escape in Pleomorphic Sarcomas
por: Darmusey, Lucie, et al.
Publicado: (2021)

The cost-saving effect of centralized histological reviews with soft tissue and visceral sarcomas, GIST, and desmoid tumors: The experiences of the pathologists of the French Sarcoma Group
por: Perrier, Lionel, et al.
Publicado: (2018)

Genome-wide CRISPR/Cas9 library screening identified ATM signaling network genes as critical drivers for resistance to ATR inhibition in soft-tissue sarcomas: synthetic lethality and therapeutic implications
por: Spalato-Ceruso, M, et al.
Publicado: (2023)

GSK3-beta as a candidate therapeutic target in soft tissue sarcomas
por: Verbeke, S., et al.
Publicado: (2021)

CINSARC in high‐risk soft tissue sarcoma patients treated with neoadjuvant chemotherapy: Results from the ISG‐STS 1001 study
por: Frezza, Anna Maria, et al.
Publicado: (2022)

Tetraploidization of Immortalized Myoblasts Induced by Cell Fusion Drives Myogenic Sarcoma Development with DMD Deletion
por: Merle, Candice, et al.
Publicado: (2020)

Identification of a Recurrent STRN/ALK Fusion in Thyroid Carcinomas
por: Pérot, Gaëlle, et al.
Publicado: (2014)

Gene expression profiling improves prognostication by nomogram in patients with soft‐tissue sarcomas
por: Crombé, Amandine, et al.
Publicado: (2022)

MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines
por: Ohnstad, Hege O, et al.
Publicado: (2011)

Targeting epigenetics in sarcomas through EZH2 inhibition
por: Italiano, Antoine
Publicado: (2020)

Nutlin-3a for age-related macular degeneration
por: Chung, Hyewon, et al.
Publicado: (2022)

Clinical activity of regorafenib in PDGFRA-mutated gastrointestinal stromal tumor
por: Grellety, Thomas, et al.
Publicado: (2015)

Acquisition of cancer stem cell capacities after spontaneous cell fusion
por: Merle, Candice, et al.
Publicado: (2021)

Expression and role of TYRO3 and AXL as potential therapeutical targets in leiomyosarcoma
por: Dantas-Barbosa, Carmela, et al.
Publicado: (2017)

Novel Therapeutic Insights in Dedifferentiated Liposarcoma: A Role for FGFR and MDM2 Dual Targeting
por: Dadone-Montaudié, Bérengère, et al.
Publicado: (2020)

Awakening p53 in senescent cells using nutlin-3
por: Schug, Thaddeus T.
Publicado: (2009)

In Vitro Selection of Mutant HDM2 Resistant to Nutlin Inhibition
por: Wei, Siau Jia, et al.
Publicado: (2013)

Inhibition of Nutlin-Resistant HDM2 Mutants by Stapled Peptides
por: Wei, Siau Jia, et al.
Publicado: (2013)

Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
por: Fourneaux, Benjamin, et al.
Publicado: (2019)

Expression of Concern to: Identifying and targeting cancer stem cells in leiomyosarcoma: prognostic impact and role to overcome secondary resistance to PI3K/mTOR inhibition
por: Fourneaux, Benjamin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_o2da4fnt636giac5ua7hpq53rc